Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.58 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158971 | 0.80 | TOP2A (0.66) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL727291 | 0.75 | TOP2A (0.67) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9752758 | 0.74 | TOP2A (0.62) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL727062 | 0.74 | TOP2A (0.62) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL729019 | 0.73 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL27318121 | 0.73 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL728997 | 0.73 | TOP2A (0.73) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL14006976 | 0.73 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL438498 | 0.73 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL13857354 | 0.73 | TOP2A (0.73) | TOP2ATOP2BALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012081036-A2 | A PROCESS FOR PREPARATION OF 4,4'-(1-METHYL-1,2-ETHANDIYL)-BIS-(2,6-PIPERAZINEDIONE) | SEQUENT SCIENTIFIC LIMITED (IN) | 2012-06-21 | — | — | WO | claimed |
| WO-2003075910-A1 | PREVENTING AND/OR TREATING VASCULAR DISEASE, CARDIOMYOPATHY AND/OR ASSOCIATED HEART FAILURE | PROTEMIX CORPORATION LIMITED (NZ) | 2003-09-18 | — | — | WO | claimed |
| WO-2019040724-A1 | SMALL MOLECULE INHIBITORS OF MYC AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2012081036-A2 | A PROCESS FOR PREPARATION OF 4,4'-(1-METHYL-1,2-ETHANDIYL)-BIS-(2,6-PIPERAZINEDIONE) | SEQUENT SCIENTIFIC LIMITED (IN) | 2012-06-21 | — | — | WO | disclosed |
| WO-2010005851-A1 | COMBINATION THERAPY FOR TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-01-14 | — | — | WO | disclosed |
| WO-2008134630-A1 | DEXRAZOXANE COMPOUNDS FOR CARDIOPROTECTION | APT PHARMACEUTICALS (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2007053415-A2 | AGENTS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20050245466-A1 | Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy | THE UNIVERSITY OF LIVERPOOL (GB) | 2005-11-03 | — | — | US | disclosed |
| EP-1490051-A1 | USE OF TOPOISOMERASE INHIBITORS AND HEAT SHOCK PROTEIN 90 INHIBITORS FOR USE IN CHEMOTHERAPY | THE UNIVERSITY OF LIVERPOOL (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003099296-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003082266-A1 | USE OF TOPOISOMERASE INHIBITORS AND HEAT SHOCK PROTEIN 90 INHIBITORS FOR USE IN CHEMOTHERAPY | UNIVERSITY OF LIVERPOOL (GB) | 2003-10-09 | — | — | WO | disclosed |
| EP-0330381-B1 | Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes | ERBAMONT INC (US) | 1995-05-24 | — | — | EP | disclosed |
| WO-1993021938-A1 | METHODS FOR TREATING CANCER USING HIGH-DOSE EPIRUBICIN | ADRIA LABORATORIES (US) | 1993-11-11 | — | — | WO | disclosed |
| WO-1991000729-A2 | BIS-DIOXOPIPERAZINES, AND THEIR USE AS PROTECTING AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-01-24 | — | — | WO | disclosed |
| WO-1991000854-A1 | N,N'-DICARBOXYMETHYL, N,N'-DIAMINOCARBONYLMETHYL-DIAMINOALKANE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-01-24 | — | — | WO | disclosed |
| US-4963679-A | Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes | ERBAMONT, INC. (US) | 1990-10-16 | — | — | US | disclosed |
| EP-0330381-A1 | Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes | ERBAMONT, INC. (US) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245466-A1 | Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy | HSP90AB2P, HSP90AB1, HSP90AA1 | TOP2A 4/4885TOP2B 11/4885ALDH1A1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.